1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2017;71(1):96-108. https://doi.org/10.1016/j.eururo.2016.06.010 https://pubmed.ncbi.nlm.nih.gov/27370177 
2. Casilla-Lennon MM, Choi SK, Deal AM, Bensen JT, Narang G, Filippou P, et al. Financial Toxicity among Patients with Bladder Cancer: Reasons for Delay in Care and Effect on Quality of Life. J Urol. 2018;199(5):1166-73. https://doi.org/10.1016/j.juro.2017.10.049 https://pubmed.ncbi.nlm.nih.gov/29155338 
3. Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, et al. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation. J Urol. 2018;199(1):229-36. https://doi.org/10.1016/j.juro.2017.07.010 https://pubmed.ncbi.nlm.nih.gov/28709886 
4. Park S, Jee SH, Shin HR, Park EH, Shin A, Jung KW, et al. Attributable fraction of tobacco smoking on cancer using population-based nationwide cancer incidence and mortality data in Korea. BMC Cancer. 2014;14(1):406. https://doi.org/10.1186/1471-2407-14-406 https://pubmed.ncbi.nlm.nih.gov/24902960 
5. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA. 2014;311(2):183-92. https://doi.org/10.1001/jama.2013.284692 https://pubmed.ncbi.nlm.nih.gov/24399557 
6. Moolgavkar SH, Stevens RG. Smoking and cancers of bladder and pancreas: risks and temporal trends. J Natl Cancer Inst. 1981;67(1):15-23. https://pubmed.ncbi.nlm.nih.gov/6942186 
7. Eriksen M, Mackay J, Schluger N, Islami Gomeshtapeh F, Drope J. The tobacco atlas. 5th ed. New York: American Cancer Society; 2015. 
8. Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103(24):1827-39. https://doi.org/10.1093/jnci/djr483 https://pubmed.ncbi.nlm.nih.gov/22158127 
9. Steinmaus C, Miller MD, Cushing L, Blount BC, Smith AH. Combined effects of perchlorate, thiocyanate, and iodine on thyroid function in the National Health and Nutrition Examination Survey 2007-08. Environ Res. 2013;123:17-24. https://doi.org/10.1016/j.envres.2013.01.005 https://pubmed.ncbi.nlm.nih.gov/23473920 
10. Antonova O, Toncheva D, Grigorov E. Bladder cancer risk from the perspective of genetic polymorphisms in the carcinogen metabolizing enzymes. J BUON. 2015;20(6):1397-406. https://pubmed.ncbi.nlm.nih.gov/26854433 
11. Jost SP, Gosling JA, Dixon JS. The morphology of normal human bladder urothelium. J Anat. 1989;167:103-15. https://pubmed.ncbi.nlm.nih.gov/2630525 
12. Ovčak Z. Klasifikacija urotelnih tumorjev sečnega mehurja WHO/ISUP (WHO/ISUP classification of the urothelial tumors of the urinary bladder). Zdr Vestn. 2005;74:529-33. 
13. Mertens LS, Neuzillet Y, Horenblas S, van Rhijn BW. Landmarks in non-muscle-invasive bladder cancer. Nat Rev Urol. 2014;11(8):476-80. https://doi.org/10.1038/nrurol.2014.130 https://pubmed.ncbi.nlm.nih.gov/24980189 
14. Epstein JI, Amin MB, Reuter VR, Mostofi FK; Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22(12):1435-48. https://doi.org/10.1097/00000478-199812000-00001 https://pubmed.ncbi.nlm.nih.gov/9850170 
15. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al.; European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639-53. https://doi.org/10.1016/j.eururo.2013.06.003 https://pubmed.ncbi.nlm.nih.gov/23827737 
16. Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int. 2008;102(9b):1242-6. https://doi.org/10.1111/j.1464-410X.2008.07966.x https://pubmed.ncbi.nlm.nih.gov/19035888 
17. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176(6 Pt 1):2414-22. https://doi.org/10.1016/j.juro.2006.08.004 https://pubmed.ncbi.nlm.nih.gov/17085118 
18. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK; International Collaboration of Trialists; et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171-7. https://doi.org/10.1200/JCO.2010.32.3139 https://pubmed.ncbi.nlm.nih.gov/21502557 
19. Nomura S, Suzuki Y, Takahashi R, Terasaki M, Kimata R, Hamasaki T, et al. Snail expression and outcome in T1 high-grade and T2 bladder cancer: a retrospective immunohistochemical analysis. BMC Urol. 2013;13(1):73. https://doi.org/10.1186/1471-2490-13-73 https://pubmed.ncbi.nlm.nih.gov/24354468 
20. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006;24(3):296-304. https://doi.org/10.1007/s00345-006-0061-7 https://pubmed.ncbi.nlm.nih.gov/16518661 
21. Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013;37(3):219-25. https://doi.org/10.1016/j.canep.2013.02.002 https://pubmed.ncbi.nlm.nih.gov/23485480 
22. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643-53. https://doi.org/10.1158/0008-5472.CAN-07-6611 https://pubmed.ncbi.nlm.nih.gov/18974103 
23. Ghosh M, Brancato SJ, Agarwal PK, Apolo AB. Targeted therapies in urothelial carcinoma. Curr Opin Oncol. 2014;26(3):305-20. https://doi.org/10.1097/CCO.0000000000000064 https://pubmed.ncbi.nlm.nih.gov/24685646 
24. Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC, Swanton C. Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. Eur Urol. 2015;67(4):729-37. https://doi.org/10.1016/j.eururo.2014.04.014 https://pubmed.ncbi.nlm.nih.gov/24836153 
25. Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res. 2009;69(23):8958-66. https://doi.org/10.1158/0008-5472.CAN-09-2045 https://pubmed.ncbi.nlm.nih.gov/19903839 
26. Kreft ME, Hudoklin S, Sterle M. Establishment and characterization of primary and subsequent subcultures of normal mouse urothelial cells. Folia Biol (Praha). 2005;51(5):126-32. https://pubmed.ncbi.nlm.nih.gov/16285205 
27. Višnjar T, Kocbek P, Kreft ME. Hyperplasia as a mechanism for rapid resealing urothelial injuries and maintaining high transepithelial resistance. Histochem Cell Biol. 2012;137(2):177-86. https://doi.org/10.1007/s00418-011-0893-0 https://pubmed.ncbi.nlm.nih.gov/22127649 
28. Masters JR, Petzoldt JL. In vitro studies on the pathogenesis of bladder cancer. Verh Dtsch Ges Pathol. 1993;77:157-60. https://pubmed.ncbi.nlm.nih.gov/7511275 
29. van Kessel KE, Zuiverloon TC, Alberts AR, Boormans JL, Zwarthoff EC. Targeted therapies in bladder cancer: an overview of in vivo research. Nat Rev Urol. 2015;12(12):681-94. https://doi.org/10.1038/nrurol.2015.231 https://pubmed.ncbi.nlm.nih.gov/26390971 
30. Sens DA, Park S, Gurel V, Sens MA, Garrett SH, Somji S. Inorganic cadmium- and arsenite-induced malignant transformation of human bladder urothelial cells. Toxicol Sci. 2004;79(1):56-63. https://doi.org/10.1093/toxsci/kfh086 https://pubmed.ncbi.nlm.nih.gov/14976345 
31. DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. 2012;148(6):1132-44. https://doi.org/10.1016/j.cell.2012.02.032 https://pubmed.ncbi.nlm.nih.gov/22424225 
32. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 1998-1999;17(3):279-84. https://doi.org/10.1023/A:1006140513233 https://pubmed.ncbi.nlm.nih.gov/10352881 
33. Kyker KD, Culkin DJ, Hurst RE. A model for 3-dimensional growth of bladder cancers to investigate cell-matrix interactions. Urol Oncol. 2003;21(4):255-61. https://doi.org/10.1016/S1078-1439(02)00279-X https://pubmed.ncbi.nlm.nih.gov/12954494 
34. Resnik N, Prezelj T, De Luca GM, Manders E, Polishchuk R, Veranič P, et al. Helical organization of microtubules occurs in a minority of tunneling membrane nanotubes in normal and cancer urothelial cells. Sci Rep. 2018;8(1):17133. https://doi.org/10.1038/s41598-018-35370-y https://pubmed.ncbi.nlm.nih.gov/30459350 
35. Ogorevc E, Hudoklin S, Veranič P, Kralj-Iglič V. Extracellular vesicle-mediated transfer of membranous components from the highly malignant T24 urinary carcinoma cell line to the non-malignant RT4 urinary papilloma cell line. Protoplasma. 2014;251(3):699-702. https://doi.org/10.1007/s00709-013-0544-5 https://pubmed.ncbi.nlm.nih.gov/24019014 
36. Lainšček D, Kadunc L, Keber MM, Bratkovič IH, Romih R, Jerala R. Delivery of an Artificial Transcription Regulator dCas9-VPR by Extracellular Vesicles for Therapeutic Gene Activation. ACS Synth Biol. 2018;7(12):2715-25. https://doi.org/10.1021/acssynbio.8b00192 https://pubmed.ncbi.nlm.nih.gov/30513193 
37. Ibrahiem EH, Nigam VN, Brailovsky CA, Madarnas P, Elhilali M. Orthotopic implantation of primary N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide-induced bladder cancer in bladder submucosa: an animal model for bladder cancer study. Cancer Res. 1983;43(2):617-22. https://pubmed.ncbi.nlm.nih.gov/6848183 
38. Günther JH, Jurczok A, Wulf T, Brandau S, Deinert I, Jocham D, et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res. 1999;59(12):2834-7. https://pubmed.ncbi.nlm.nih.gov/10383142 
39. Clayson DB, Fishbein L, Cohen SM. Effects of stones and other physical factors on the induction of rodent bladder cancer. Food Chem Toxicol. 1995;33(9):771-84. https://doi.org/10.1016/0278-6915(95)00044-3 https://pubmed.ncbi.nlm.nih.gov/7557750 
40. Knapp DW, Henry CJ, Widmer WR, Tan KM, Moore GE, Ramos-Vara JA, et al. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med. 2013;27(1):126-33. https://doi.org/10.1111/jvim.12013 https://pubmed.ncbi.nlm.nih.gov/23205923 
41. Knapp DW, Ramos-Vara JA, Moore GE, Dhawan D, Bonney PL, Young KE. Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development. ILAR J. 2014;55(1):100-18. https://doi.org/10.1093/ilar/ilu018 https://pubmed.ncbi.nlm.nih.gov/24936033 
42. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006;66(7):3351-4. https://doi.org/10.1158/0008-5472.CAN-05-3627 https://pubmed.ncbi.nlm.nih.gov/16585151 
43. Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget. 2015;6(25):21522-32. https://doi.org/10.18632/oncotarget.3974 https://pubmed.ncbi.nlm.nih.gov/26041878 
44. Matsuo T, Miyata Y, Asai A, Sagara Y, Furusato B, Fukuoka J, et al. Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer. PLoS One. 2017;12(1):e0171091. https://doi.org/10.1371/journal.pone.0171091 https://pubmed.ncbi.nlm.nih.gov/28141864 
45. Slocum SL, Kensler TW. Nrf2: control of sensitivity to carcinogens. Arch Toxicol. 2011;85(4):273-84. https://doi.org/10.1007/s00204-011-0675-4 https://pubmed.ncbi.nlm.nih.gov/21369766 
46. Gofrit ON, Birman T, Dinaburg A, Ayesh S, Ohana P, Hochberg A. Chemically induced bladder cancer—a sonographic and morphologic description. Urology. 2006;68(1):231-5. https://doi.org/10.1016/j.urology.2006.03.022 https://pubmed.ncbi.nlm.nih.gov/16844461 
47. Ariel I, Ayesh S, Gofrit O, Ayesh B, Abdul-Ghani R, Pizov G, et al. Gene expression in the bladder carcinoma rat model. Mol Carcinog. 2004;41(2):69-76. https://doi.org/10.1002/mc.20046 https://pubmed.ncbi.nlm.nih.gov/15378645 
48. Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer. 1972;8(6):587-94. https://doi.org/10.1016/0014-2964(72)90137-5 https://pubmed.ncbi.nlm.nih.gov/4651993 
49. Kunze E, Chowaniec J. Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the urinary bladder. IARC Sci Publ. 1990(99):345-97. https://pubmed.ncbi.nlm.nih.gov/2093653 
50. Okajima E, Hiramatsu T, Hirao K, Ijuin M, Hirao Y, Babaya K, et al. Urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in dogs. Cancer Res. 1981;41(5):1958-66. https://pubmed.ncbi.nlm.nih.gov/7214364 
51. Vasconcelos-Nóbrega C, Colaço A, Lopes C, Oliveira PA. Review: BBN as an urothelial carcinogen. In Vivo. 2012;26(4):727-39. https://pubmed.ncbi.nlm.nih.gov/22773588 
52. Tsuda H, Miyata Y, Hagiwara A, Hasegawa R, Shirai T, Ito N. Damage and repair of DNA in urinary bladder epithelium of rats treated with N-butyl-N-(4-hydroxybutyl) nitrosamine. Gan. 1977;68(6):781-3. https://pubmed.ncbi.nlm.nih.gov/598647 
53. Airoldi L, Magagnotti C, Bonfanti M, Fanelli R. Alpha-oxidative metabolism of the bladder carcinogens N-nitrosobutyl(4-hydroxybutyl)amine and N-nitrosobutyl(3-carboxypropyl)amine within the rat isolated bladder. Carcinogenesis. 1990;11(8):1437-40. https://doi.org/10.1093/carcin/11.8.1437 https://pubmed.ncbi.nlm.nih.gov/2387032 
54. Cohen SM, Ohnishi T, Clark NM, He J, Arnold LL. Investigations of rodent urinary bladder carcinogens: collection, processing, and evaluation of urine and bladders. Toxicol Pathol. 2007;35(3):337-47. https://doi.org/10.1080/01926230701197115 https://pubmed.ncbi.nlm.nih.gov/17455081 
55. Cohen SM. Urinary bladder carcinogenesis. Toxicol Pathol. 1998;26(1):121-7. https://doi.org/10.1177/019262339802600114 https://pubmed.ncbi.nlm.nih.gov/9502394 
56. Ohtani M, Kakizoe T, Nishio Y, Sato S, Sugimura T, Fukushima S, et al. Sequential changes of mouse bladder epithelium during induction of invasive carcinomas by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 1986;46(4 Pt 2):2001-4. https://pubmed.ncbi.nlm.nih.gov/3948177 
57. Zupančič D, Ovčak Z, Vidmar G, Romih R. Altered expression of UPIa, UPIb, UPII, and UPIIIa during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats. Virchows Arch. 2011;458(5):603-13. https://doi.org/10.1007/s00428-011-1045-6 https://pubmed.ncbi.nlm.nih.gov/21301865 
58. Zupančič D, Kreft ME, Romih R. Selective binding of lectins to normal and neoplastic urothelium in rat and mouse bladder carcinogenesis models. Protoplasma. 2014;251(1):49-59. https://doi.org/10.1007/s00709-013-0524-9 https://pubmed.ncbi.nlm.nih.gov/23828036 
59. Chan ES, Patel AR, Smith AK, Klein JB, Thomas AA, Heston WD, et al. Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model. J Urol. 2009;182(6):2926-31. https://doi.org/10.1016/j.juro.2009.08.020 https://pubmed.ncbi.nlm.nih.gov/19846165 
60. Sengeløv L, Kamby C, von der Maase H. Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma. J Urol. 1996;155(1):111-4. https://doi.org/10.1016/S0022-5347(01)66562-5 https://pubmed.ncbi.nlm.nih.gov/7490804 
61. Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, Parney I, et al. Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer. 1999;81(4):638-46. https://doi.org/10.1038/sj.bjc.6690741 https://pubmed.ncbi.nlm.nih.gov/10574249 
62. Marks P, Soave A, Shariat SF, Fajkovic H, Fisch M, Rink M. Female with bladder cancer: what and why is there a difference? Transl Androl Urol. 2016;5(5):668-82. https://doi.org/10.21037/tau.2016.03.22 https://pubmed.ncbi.nlm.nih.gov/27785424 
63. Erman A, Kapun G, Novak S, Pavlin M, Dražić G, Drobne D, et al. How cancer cells attach to urinary bladder epithelium in vivo: study of the early stages of tumorigenesis in an orthotopic mouse bladder tumor model. Histochem Cell Biol. 2019;151(3):263-73. https://doi.org/10.1007/s00418-018-1738-x https://pubmed.ncbi.nlm.nih.gov/30280243 
64. Abate-Shen C, Pandolfi PP. Effective utilization and appropriate selection of genetically engineered mouse models for translational integration of mouse and human trials. Cold Spring Harb Protoc. 2013;2013(11):pdb.top078774. https://doi.org/10.1101/pdb.top078774 https://pubmed.ncbi.nlm.nih.gov/24173311 
65. Kobayashi T, Owczarek TB, McKiernan JM, Abate-Shen C. Modelling bladder cancer in mice: opportunities and challenges. Nat Rev Cancer. 2015;15(1):42-54. https://doi.org/10.1038/nrc3858 https://pubmed.ncbi.nlm.nih.gov/25533675 
66. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-22. https://doi.org/10.1038/nature12965 https://pubmed.ncbi.nlm.nih.gov/24476821 
67. Wu XR, Lin JH, Walz T, Häner M, Yu J, Aebi U, et al. Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem. 1994;269(18):13716-24. https://pubmed.ncbi.nlm.nih.gov/8175808 
68. Wu XR, Manabe M, Yu J, Sun TT. Large scale purification and immunolocalization of bovine uroplakins I, II, and III. Molecular markers of urothelial differentiation. J Biol Chem. 1990;265(31):19170-9. https://pubmed.ncbi.nlm.nih.gov/2229070 
69. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 1999;59(14):3512-7. https://pubmed.ncbi.nlm.nih.gov/10416618 
70. Ayala de la Peña F, Kanasaki K, Kanasaki M, Tangirala N, Maeda G, Kalluri R. Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem. 2011;286(23):20778-87. https://doi.org/10.1074/jbc.M110.198069 https://pubmed.ncbi.nlm.nih.gov/21388952 
71. Stone R, Sabichi AL, Gill J, Lee IL, Adegboyega P, Dai MS, et al. Identification of genes correlated with early-stage bladder cancer progression. Cancer Prev Res (Phila). 2010;3(6):776-86. https://doi.org/10.1158/1940-6207.CAPR-09-0189 https://pubmed.ncbi.nlm.nih.gov/20501863 
72. Wu XR. Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer Metastasis Rev. 2009;28(3-4):281-90. https://doi.org/10.1007/s10555-009-9189-4 https://pubmed.ncbi.nlm.nih.gov/20012171 
73. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009;23(6):675-80. https://doi.org/10.1101/gad.1772909 https://pubmed.ncbi.nlm.nih.gov/19261747 
74. Ramesh N, Memarzadeh B, Ge Y, Frey D, VanRoey M, Rojas V, et al. Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium. Mol Ther. 2004;10(4):697-705. https://doi.org/10.1016/j.ymthe.2004.07.002 https://pubmed.ncbi.nlm.nih.gov/15451454 
75. Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila). 2009;2(12):1008-14. https://doi.org/10.1158/1940-6207.CAPR-09-0169 https://pubmed.ncbi.nlm.nih.gov/19952358 
76. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J. 1997;14(5):569-76. https://doi.org/10.1023/A:1018580324971 https://pubmed.ncbi.nlm.nih.gov/9298689 
77. Višnjar T, Romih R, Zupančič D. Lectins as possible tools for improved urinary bladder cancer management. Glycobiology. 2019;29(5):355-65. https://doi.org/10.1093/glycob/cwz001 https://pubmed.ncbi.nlm.nih.gov/30689891 
78. Zupančič D, Kreft ME, Grdadolnik M, Mitev D, Iglič A, Veranič P. Detonation nanodiamonds are promising nontoxic delivery system for urothelial cells. Protoplasma. 2018;255(1):419-23. https://doi.org/10.1007/s00709-017-1146-4 https://pubmed.ncbi.nlm.nih.gov/28741141 
79. Imani R, Veranič P, Iglič A, Kreft ME, Pazoki M, Hudoklin S. Combined cytotoxic effect of UV-irradiation and TiO2 microbeads in normal urothelial cells, low-grade and high-grade urothelial cancer cells. Photochem Photobiol Sci. 2015;14(3):583-90. https://doi.org/10.1039/C4PP00272E https://pubmed.ncbi.nlm.nih.gov/25385056 
80. Erman A, Veranič P. The Use of Polymer Chitosan in Intravesical Treatment of Urinary Bladder Cancer and Infections. Polymers (Basel). 2018;10(3):E265. https://doi.org/10.3390/polym10030265 https://pubmed.ncbi.nlm.nih.gov/30966300 
